Cited by 588Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Open access

The STABILITY Investigators·2014·New England Journal of Medicine

DOI 10.1056/nejmoa1315878

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS: In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS: During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02). CONCLUSIONS: In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1315878

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
Concept of Vulnerable/Unstable Plaque
Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D., & Virmani, R. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179739 · Cited by 1,193
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
Steg, P. G., Greenlaw, N., Tardif, J., Tendera, M., Ford, I., Kääb, S., Abergel, H., Fox, K. M., Ferrari, R., & on behalf of the CLARIFY Registry Investigators (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs289 · Cited by 653
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
‡ (2010) · The Lancet · doi:10.1016/s0140-6736(10)60319-4 · Cited by 595
Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque
Serruys, P. W. J. C., García‐García, H. M., Buszman, P. E., Erné, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, Ø., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 498
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Postle, A. D., Fenning, R. S., Bollinger, J. G., Hoffman, B. E., et al. (2008) · Nature Medicine · doi:10.1038/nm.1870 · Cited by 389
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
Macphee, C. H., Moores, K., Boyd, H., Dhanak, D., Ife, R. J., Leach, C. A., Leake, D. S., Milliner, K. J., Patterson, R. A., Suckling, K. E., et al. (1999) · Biochemical Journal · doi:10.1042/bj3380479 · Cited by 359
Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease
Brosius, F. C., Hostetter, T. H., Kelepouris, E., Mitsnefes, M. M., Moe, S. M., Moore, M. A., Pennathur, S., Smith, G. L., & Wilson, P. W. F. (2006) · Circulation · doi:10.1161/circulationaha.106.177321 · Cited by 325
Lipoprotein-Associated Phospholipase A 2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis
Kolodgie, F. D., BURKE, A. P., Skorija, K., Ladich, E. R., Kutys, R., Makuria, A. T., & Virmani, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000244681.72738.bc · Cited by 307

Show all 22 references

Research works printed but not linked: 1

10.1042/0264-6021:3380479 · DOI

Sorted by citations

Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
The immunology of atherosclerosis
Gisterå, A., & Hansson, G. K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.51 · Cited by 982
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Genetics of coronary artery disease: discovery, biology and clinical translation
Khera, A. V., & Kathiresan, S. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.160 · Cited by 659
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 651
The Role of Oxidative Stress in Atherosclerosis
Batty, M., Bennett, M. R., & Yu, E. (2022) · Cells · doi:10.3390/cells11233843 · Cited by 586
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial
O’Donoghue, M. L., Braunwald, E., White, H. D., Steen, D. P., Lukas, M. A., Tarka, E., Steg, P. G., Hochman, J. S., Bode, C., Maggioni, A. P., et al. (2014) · JAMA · doi:10.1001/jama.2014.11061 · Cited by 456
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation
Hijazi, Z., Lindbäck, J., Alexander, J. H., Hanna, M., Held, C., Hylek, E. M., Lopes, R. D., Oldgren, J., Siegbahn, A., Stewart, R. A. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw054 · Cited by 437
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
Raggi, P., Genest, J. J., Giles, J. T., Rayner, K. J., Dwivedi, G., Beanlands, R. S., & Gupta, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.014 · Cited by 447
Anti-inflammatory therapies for atherosclerosis
Bäck, M., & Hansson, G. K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.5 · Cited by 380
Genetics of Coronary Artery Disease
McPherson, R., & Tybjærg‐Hansen, A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306566 · Cited by 384
Erratum: Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.33 · Cited by 366
Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease
Liberale, L., Montecucco, F., Tardif, J., Libby, P., & Camici, G. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz961 · Cited by 363
Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity
Saleheen, D., Natarajan, P., Armean, I. M., Zhao, W., Rasheed, A., Khetarpal, S. A., Won, H.-H., Karczewski, K. J., O’Donnell-Luria, A. H., Samocha, K. E., et al. (2017) · Nature · doi:10.1038/nature22034 · Cited by 340
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T. Y., Pais, P. S., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 345
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Eslam, M., & George, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0212-0 · Cited by 315
Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
Wong, N. D., Budoff, M. J., Ferdinand, K. C., Graham, I. M., Michos, E. D., Reddy, T. K., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100335 · Cited by 327
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease
Stewart, R., Held, C., Hadziosmanovic, N., Armstrong, P. W., Cannon, C. P., Granger, C. B., Hagström, E., Hochman, J. S., Köenig, W., Lonn, E., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.017 · Cited by 310
Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Held, C., White, H. D., Stewart, R., Budaj, A., Cannon, C. P., Hochman, J. S., Köenig, W., Siegbahn, A. G., Steg, P. G., Soffer, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005077 · Cited by 301
Imaging Atherosclerosis
Tarkin, J. M., Dweck, M. R., Evans, N. R., Takx, R. A. P., Brown, A. J., Tawakol, A. A., Fayad, Z. A., & Rudd, J. H. F. (2016) · Circulation Research · doi:10.1161/circresaha.115.306247 · Cited by 290
Novel biomarkers for cardiovascular risk prediction.
Wang, J., Tan, G.-J., Han, L.-N., Bai, Y., He, M., & Liu, H. (2017) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2017.02.008 · Cited by 277
Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA 2 Inhibitor
Measom, N. D., Down, K. D., Hirst, D. J., Jamieson, C. J., Manas, E. S., Patel, V. K., & Somers, D. O. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00281 · Cited by 255
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
Webb, T. R., Erdmann, J., Stirrups, K. E., Stitziel, N. O., Masca, N. G. D., Jansen, H., Kanoni, S., Nelson, C. P., Ferrario, P. G., König, I. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.056 · Cited by 250
Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease
Esser, N., Paquot, N., & Scheen, A. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.974804 · Cited by 255
Inflammatory markers and the risk of dementia and Alzheimer's disease: a meta-analysis
Darweesh, S. K. L., Wolters, F. J., Ikram, M. A., de Wolf, F., Bos, D., & Hofman, A. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.014 · Cited by 244
The Macrophage in Cardiac Homeostasis and Disease
Lavine, K. J., Pinto, A. R., Epelman, S., Kopecky, B. J., Clemente-Casares, X., Godwin, J., Rosenthal, N., & Kovacic, J. C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2149 · Cited by 234
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial
Lo, J., Lu, M. T., Ihenachor, E. J., Wei, J., Looby, S. E. D., Fitch, K. V., Oh, J.-H., Zimmerman, C. O., Hwang, J. J., Abbara, S., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(14)00032-0 · Cited by 236
Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation
Li, X., Fang, P., Li, Y., Kuo, Y., Andrews, A. J., Nanayakkara, G., Johnson, C., Fu, H., Shan, H., Du, F., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306964 · Cited by 220
Lipoprotein‐associated phospholipase A2: The story continues
Huang, F., Wang, K., & Shen, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21597 · Cited by 212
Big data from electronic health records for early and late translational cardiovascular research: challenges and potential
Hemingway, H., Asselbergs, F. W., Danesh, J., Dobson, R., Maniadakis, N., Maggioni, A. P., van Thiel, G. J. M. W., Cronin, M., Brobert, G., Vardas, P. E., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx487 · Cited by 218
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Blood Biomarkers for Stroke Diagnosis and Management
Tatuene, J. K., & Jickling, G. C. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08530-0 · Cited by 179
Mendelian randomisation in cardiovascular research: an introduction for clinicians
Bennett, D., & Holmes, M. V. (2017) · Heart · doi:10.1136/heartjnl-2016-310605 · Cited by 181
Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence
Vrijens, B., & Heidbüchel, H. (2015) · EP Europace · doi:10.1093/europace/euu311 · Cited by 172
Sex-Based Differences in Cardiometabolic Biomarkers
Lew, J., Sanghavi, M., Ayers, C. R., McGuire, D. K., Omland, T., Atzler, D., Gore, M. O., Neeland, I. J., Berry, J. D., Khera, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.023005 · Cited by 172
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Targeting the Immune System in Atherosclerosis
Zhao, T. X., & Mallat, Z. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.083 · Cited by 161
Interleukin 6 Inhibition and Coronary Artery Disease in a High‐Risk Population: A Prospective Community‐Based Clinical Study
Bacchiega, B. C., Bacchiega, A. B. S., Usnayo, M. J. G., Bedirian, R., Singh, G., & Pinheiro, G. D. R. C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005038 · Cited by 157
A Novel Anti-Inflammatory Role of Omega-3 PUFAs in Prevention and Treatment of Atherosclerosis and Vascular Cognitive Impairment and Dementia
Simonetto, M., Infante, M., Sacco, R. L., Rundek, T., & Della‐Morte, D. (2019) · Nutrients · doi:10.3390/nu11102279 · Cited by 164
Noninvasive Molecular Imaging of Disease Activity in Atherosclerosis
Dweck, M. R., Aïkawa, E., Newby, D. E., Tarkin, J. M., Rudd, J. H. F., Narula, J., & Fayad, Z. A. (2016) · Circulation Research · doi:10.1161/circresaha.116.307971 · Cited by 148
Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond
Libby, P. (2021) · Cells · doi:10.3390/cells10040951 · Cited by 158
Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives
Lordan, R., Tsoupras, A., Zabetakis, I., & Demopoulos, C. (2019) · Molecules · doi:10.3390/molecules24234414 · Cited by 137
Novel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145
Inflammation and cardiovascular diseases: lessons from seminal clinical trials
Liberale, L., Montecucco, F., Schwarz, L., Lüscher, T. F., & Camici, G. G. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa211 · Cited by 147
Effect of Evolocumab on Coronary Plaque Composition
Nicholls, S. J., Puri, R., Anderson, T. J., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Köenig, W., Somaratne, R. M., Kassahun, H., Yang, J., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.078 · Cited by 146
Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
Pugliese, N. R., Pellicori, P., Filidei, F., Biase, N. D., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac133 · Cited by 150
Novel biomarkers of cardiovascular disease: Applications in clinical practice
Lyngbakken, M. N., Myhre, P. L., Røsjø, H. R., & Omland, T. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1525335 · Cited by 155
Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis
Gill, P., Jindal, N. L., Jagdis, A., & Vadas, P. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.04.019 · Cited by 140
Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis
Wong, N. D., Zhao, Y., Quek, R. G. W., Blumenthal, R. S., Budoff, M. J., Cushman, M., Garg, P. K., Sandfort, V., Tsai, M. Y., & López, J. A. G. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.015 · Cited by 142
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease
Lindholm, D. P., Lindbäck, J., Armstrong, P. W., Budaj, A., Cannon, C. P., Granger, C. B., Hagström, E., Held, C., Köenig, W., Östlund, O., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.030 · Cited by 143
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48
Berg, D. D., Ruff, C. T., Jarolı́m, P., Giugliano, R. P., Nordio, F., Lanz, H., Mercuri, M. F., Antman, E. M., D, E. B. M., & Morrow, D. A. (2019) · Circulation · doi:10.1161/circulationaha.118.038312 · Cited by 138
Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases
Faccini, A., Kaski, J. C., & Camici, P. G. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw018 · Cited by 138
Challenges and advances in the management of inflammation in atherosclerosis
Xing, Y., & Lin, X. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.06.016 · Cited by 147
Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis
Dou, Y., Chen, Y., Zhang, X., Xu, X., Chen, Y., Guo, J., Zhang, D., Wang, R., Li, X., & Zhang, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.035 · Cited by 133
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
Ridker, P. M., Rifai, N., MacFadyen, J., Glynn, R. J., Jiao, L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J.-C., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059410 · Cited by 131
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease
Stewart, R., Wallentin, L. C., Benatar, J. R., Danchin, N., Hagström, E., Held, C., Husted, S., Lonn, E., Stebbins, A. S., Chiswell, K., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw125 · Cited by 135
The Role of Inflammation in Cardiovascular Outcome
Montecucco, F., Liberale, L., Bonaventura, A., Vecchié, A., Dallegri, F., & Carbone, F. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0646-1 · Cited by 133
Imaging atherosclerosis with positron emission tomography
Joseph, P., & Tawakol, A. A. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw147 · Cited by 131
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease
Hagström, E., Held, C., Stewart, R., Aylward, P. E., Budaj, A., Cannon, C. P., Köenig, W., Krug‐Gourley, S., Mohler, E. R., Steg, P. G., et al. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.260570 · Cited by 124
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome
Batra, G., Lakic, T. G., Lindbäck, J., Held, C., White, H. D., Stewart, R., Köenig, W., Cannon, C. P., Budaj, A., Hagström, E., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3079 · Cited by 124
Inflammation and atherosclerosis: what is on the horizon?
Ruparelia, N., & Choudhury, R. P. (2019) · Heart · doi:10.1136/heartjnl-2018-314230 · Cited by 123
Role of Vascular Inflammation in Coronary Artery Disease: Potential of Anti-inflammatory Drugs in the Prevention of Atherothrombosis
Moreira, D. M., da Silva, R. L., Vieira, J. L., Fattah, T., Lueneberg, M. E., & Gottschall, C. A. M. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0094-z · Cited by 117
Genetics: Implications for Prevention and Management of Coronary Artery Disease
Assimes, T. L., & Roberts, R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.039 · Cited by 118
Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study
Wallentin, L. C., Eriksson, N., Olszowka, M., Grammer, T. B., Hagström, E., Held, C., Kleber, M. E., Köenig, W., März, W., Stewart, R., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003513 · Cited by 117
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108
Management of inflammation in cardiovascular diseases
Goswami, S. K., Ranjan, P., Dutta, R. K., & Verma, S. K. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105912 · Cited by 111
Arteriosclerosis e inflamación. Nuevos enfoques terapéuticos
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.04.024 · Cited by 114
Novel metabolic biomarkers of cardiovascular disease
Jensen, M. K., Bertoia, M. L., Cahill, L. E., Agarwal, I., Rimm, E. B., & Mukamal, K. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.155 · Cited by 109
Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation
Li, X., Wang, L., Fang, P., Sun, Y., Jiang, X., Wang, H., & Yang, X. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002752 · Cited by 103
The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism
Oh, M., Jang, S. Y., Lee, J.-Y., Kim, J. W., Jung, Y., Kim, J., Seo, J., Han, T., Jang, E., Son, H. Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41462-9 · Cited by 112
The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
Pirillo, A., Bonacina, F., Norata, G. D., & Catapano, A. L. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0715-0 · Cited by 97
Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease
Hagström, E., Norlund, F., Stebbins, A. S., Armstrong, P. W., Chiswell, K., Granger, C. B., López-Sendón, J., Pella, D., Soffer, J., Sy, R., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12692 · Cited by 97
Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves
Salaün, E., Mahjoub, H., Dahou, A., Mathieu, P., Larose, É., Després, J., Rodés‐Cabau, J., Arsenault, B. J., Puri, R., Clavel, M.-A. A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.064 · Cited by 93
Emerging biomarkers for the detection of cardiovascular diseases
Thupakula, S., Nimmala, S. S. R., Ravula, H., Chekuri, S., & Padiya, R. (2022) · The Egyptian Heart Journal · doi:10.1186/s43044-022-00317-2 · Cited by 91
Critical appraisal of inflammatory markers in cardiovascular risk stratification
Krintus, M., Koziński, M., Kubica, J., & Sypniewska, G. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.913549 · Cited by 91
Anti-inflammatory approaches to ischaemic stroke prevention
Kelly, P. J., Murphy, S., Coveney, S. A., Purroy, F. F., Lemmens, R., Tsivgoulis, G. K., & Price, C. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314817 · Cited by 90
Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation
Lv, S., Zeng, Z., Gan, W., Wang, W., Li, T.-G., Hou, Y., Yan, Z., Zhang, R., & Yang, M. H. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00703-7 · Cited by 91
Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy
Held, C., Hadziosmanovic, N., Aylward, P. E., Hagström, E., Hochman, J. S., Stewart, R. A. H., White, H. D., & Wallentin, L. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023667 · Cited by 94
Innate and Adaptive Immune Response in Fabry Disease
Mauhin, W., Lidove, O., Masat, E., Mingozzi, F., Mariampillai, K., Ziza, J.-M., & Benvéniste, O. (2015) · JIMD Reports · doi:10.1007/8904_2014_371 · Cited by 85
Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2
Nikolaou, A. I., Kokotou, M. G., Vasilakaki, S., & Kokotos, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.08.009 · Cited by 87
Early Detection and Treatment of the Vulnerable Coronary Plaque
Bom, M. J., van der Heijden, D. J., Kedhi, E., der Heyden, J. V., Meuwissen, M., Knaapen, P., Timmer, S. A. J., & van Royen, N. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005973 · Cited by 88
Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review
Fava, C., & Montagnana, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00055 · Cited by 86
Mendelian randomization studies
Ference, B. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000247 · Cited by 84
INPP5D regulates inflammasome activation in human microglia
Chou, V., Pearse, R. V., Aylward, A. J., Ashour, N., Taga, M., Terzioglu, G., Fujita, M., Fancher, S. B., Sigalov, A., Benoit, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42819-w · Cited by 79
Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases
Potere, N., Bonaventura, A., & Abbate, A. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319980 · Cited by 85
Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk
Soria-Florido, M. T., Castañer, O., Lassale, C. M., Estruch, R., Salas‐Salvadó, J., Martínez‐González, M. Á., Corella, D., Ros, E., Arós, F., Elosúa, R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041658 · Cited by 79
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman, R., Merdler, I., Case, B. C., Waksman, O., & Porto, I. (2023) · EuroIntervention · doi:10.4244/eij-d-23-00606 · Cited by 88
Large animal models of atherosclerosis – new tools for persistent problems in cardiovascular medicine
Shim, J., Al-Mashhadi, R. H., Sørensen, C. B., & Bentzon, J. F. (2015) · The Journal of Pathology · doi:10.1002/path.4646 · Cited by 75
Elevated dietary ω-6 polyunsaturated fatty acids induce reversible peripheral nerve dysfunction that exacerbates comorbid pain conditions
Boyd, J. T., Lococo, P. M., Furr, A. R., Bendele, M., Tram, M., Li, Q., Chang, F.-M., Colley, M. E., Samenuk, G. M., Arris, D., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00410-x · Cited by 71
Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations
Wang, K., Shi, X., Zhu, Z., Hao, X., Chen, L., Cheng, S., Foo, R., & Wang, C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01067-1 · Cited by 71
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial
Vidal‐Petiot, E., Stebbins, A., Chiswell, K., Ardissino, D., Aylward, P. E., Cannon, C. P., Corrales, M. A. R., Held, C., López-Sendón, J. L., Stewart, R., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx250 · Cited by 72
Current and future trends in the lipid lowering therapy
Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 69
Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy
Hilvo, M., Wallentin, L. C., Lakic, T. G., Held, C., Kauhanen, D., Jylhä, A., Lindbäck, J., Siegbahn, A. G., Granger, C. B., Köenig, W., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015258 · Cited by 68
Self-citation
Lipoprotein‐Associated Phospholipase A 2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
Wallentin, L. C., Held, C., Armstrong, P. W., Cannon, C. P., Davies, R. Y., Granger, C. B., Hagström, E., Harrington, R. A., Hochman, J. S., Köenig, W., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003407 · Cited by 66
Self-citation
New methods to image unstable atherosclerotic plaques
Andrews, J. P. M., Fayad, Z. A., & Dweck, M. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.021 · Cited by 66

Authors: The STABILITY Investigators
Affiliations: University of Auckland (NZ)
Corresponding author: The STABILITY Investigators
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2014-05
Volume: 370
Issue: 18
Pages: 1702-1711
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1315878
OpenAlex: W1572528121
Cited by: 579
References: 22
Citations by year: 2026: 23 · 2025: 34 · 2024: 33 · 2023: 27 · 2022: 47 · 2021: 38 · 2020: 34 · 2019: 36 · 2018: 48 · 2017: 63 · 2016: 71 · 2015: 85 · 2014: 37
FWCI: 85.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
UEA Digital Repository (University of East Anglia) (submittedVersion)
Funders: Uppsala Universitet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: darapladib, lipoprotein-associated phospholipase A2, stable coronary artery disease, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, major coronary events, all-cause mortality, atherosclerotic plaque vulnerability, lipid-lowering therapy, unstable angina
MeSH terms: Aged, Benzaldehydes, Biphenyl Compounds, Coronary Artery Disease, Coronary Disease, Diethylamines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Oximes, Pyrimidinones, Sulfides, Treatment Failure, Stroke, Kaplan-Meier Estimate, Phospholipase A2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks